|
|
 |
|
Viewing report
|
|
|
|
Outcomes-Based Pharmaceutical Pricing
Cutting Edge Information, Sep 2008, Pages: 124
Optimize pricing planning to satisfy customer group needs in this report from Cutting Edge Information:
The pricing landscape has changed dramatically over the past decade. In the 1990s and even a few years ago, pricing was almost an afterthought — pricing plans were formed and carried out during ramp-up to product launch; there was less regulatory scrutiny; the concept of health outcomes analysis was still taking shape, and any pharmacoeconomic data that companies were able to provide was better than none.
Today, however, strategic pricing is more important than ever before. Pharmaceutical and biotechnology companies' pricing teams contend with unrelenting pressures. They must manage increased scrutiny from different sides — government agencies, the media and the public — over pharmaceutical pricing, while meeting multiple stakeholders' needs: third-party payers, physicians and patients. Adding to the complexity are ever-rising clinical development costs and shrinking pipelines in a constantly changing, global marketplace.
As a result of these challenges, pharmaceutical pricing has become payer-driven and value-based. But life sciences companies are also recognizing the vital importance of strategic pricing. Rather than coming at the tail end of a drug's development, pricing planning is being integrated into drug development. The pricing department, in fact, is now a key driver in lifecycle management.
Outcomes-Based Pharmaceutical Pricing: Meeting Stakeholder Needs examines these industry trends. It provides action items to resolve pricing departments' most pressing problems. Above all, it shows how forward-thinking companies maximize profits by addressing customers' preferences and ensuring that they set the right prices for their products.
Use the report to:
- Maximize pricing departments' strategic capabilities
- Improve pricing decision making
- Streamline the pricing process
- Coordinate pricing and launch sequence strategies
- Improve cross-functional communication and involvement in pricing plans
- Benchmark pricing department resources
Product samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
Strategic Overview of Pharmaceutical Pricing and Reimbursement in the Major Markets
Pharmaceutical Pricing and Reimbursement in Japan, 2008
Pricing and Reimbursement: Innovative Risk-Sharing Strategies
Valuing Pharmaceutical Innovation: Pricing and Reimbursement for Innovative Therapies
Pharmaceutical Pricing and Reimbursement in the United Kingdom, 2008
Pricing and Reimbursement in the United Arab Emirates
Mobile Pricing Innovations - The price of pricing
Orphan Drugs in Europe: Pricing, Reimbursement, Funding and Market Access Issues
The Pricing and Reimbursement Environment for Neurology Drugs
Special Report: Pharmaceutical Pricing and Reimbursement in Germany, 2008
Pricing & Reimbursement - Seven Major Markets Update
Pharmaceutical Pricing and Reimbursement in Italy, 2008
|
|
|
|
